You are here

Therapeutic Advances in Drug Safety

Therapeutic Advances in Drug Safety


Editor-in-Chief
Managing Editor
Elena Conroy SAGE Publications Ltd, UK
Associate Editors
Joris Berwaerts MD J&J Pharmaceutical Research & Development, USA
Matthew P. Doogue BSc, MBCHB, DipPaed, FRACP Univeristy of Otago Christchurch, New Zealand
Roy Soiza MB, ChB. MRCP NHS Grampian, Aberdeen, UK
Stephen Waring BMedSci, MB, BCh, BAO, PhD York Hospitals NHS Trust, UK
Lesley Wise Wise Pharmacovigilance and Risk Management Ltd, London, UK


eISSN: 20420994 | ISSN: 20420986 | Current volume: 9 | Current issue: 11 Frequency: Monthly

Journal Highlights

  • Unofficial impact factor: 2.838 (data from Clarivate Analytics Web of Knowledge)
  • Listed in PubMed and freely available via PubMed Central 
  • Indexed in Web of Science and the Emerging Sources Citation Index (ESCI) 
  • Rigorous peer review Rapid publication
  • Free to publish (no article fees)
  • 480,000 article views on PubMed Central in 2017 Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies across all areas of drug safety. 

The journal is a member of the Committee on Publication Ethics (COPE).

Submission information

Submit your manuscript today at http://mc.manuscriptcentral.com/tads.

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access article processing charge (APC) information

From 1st January 2019, this journal will become a fully open access journal. To facilitate this transition articles will be published under a Creative Commons licence.

There will be no article processing charges (APCs) associated with publishing in the journal for an introductory period.

Contact

Please direct any enquiries to Elena.Conroy@sagepub.co.uk.


Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The editors welcome original research articles across all area of drug safety.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies - all phases. Letters to the Editor and Case Reports will also be considered.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.
The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 3 weeks from acceptance.
Editorial Board
Anna Birna Almarsdóttir PdD, MS, MSc University of Copenhagen, Copenhagen, Denmark
Andrew Bate PhD Pfizer Inc., New York, NY, USA
Christopher Beer MB, BS, GradCertHPEd, PhD, FRACP Royal Perth Hospital, Perth, WA, Australia
J Simon Bell PhD Monash University, Melbourne, Australia
Phil Berry MBBS, Mphil Independent Pharmaceutical Consultant, Geneva, Switzerland
Kin-Wei Chan MD, ScD, FISPE Harvard School of Public Health, Boston, MA, USA
Antonio Cherubini MD, PhD IRCCS INRCA, Ancona, Italy
Bernard Cheung MA, MB BChir, PhD, MRCP, FRCP, FCP, FHKCP, FHKAM (Medicine) The University of Hong Kong, Hong Kong
Claire Davies Medicines and Healthcare Products Regulatory Agency, London, UK
Jacques Descotes MD, PharmD, PhD Lyon University Hospitals (HCL), Lyon, France
Alex Dodoo B.Pharm, MSc, PhD, FPSGH, FPCPharm University of Ghana Medical School, Accra, Ghana
Stanley Garbus MD, MPH Garbus Consulting, West New York, NJ, USA
Phil Hannaford MBChB University of Aberdeen, Aberdeen, UK
Manfred Hauben MD, PhD New York, NY, USA
Sarah Hilmer BScMed, MBBS, FRACP, PhD Royal North Shore Hospital, St Leonards, NSW, Australia
Paul Jansen MD, PhD University Medical Centre, Utrecht, Netherlands
Neil Kaplowitz MD University of Southern California, Los Angeles, CA, USA
Stephen Leslie BSc, MB ChB, PhD, FRCP Raigmore Hospital, Inverness, UK
Sunny Linnebur Pharm.D, FCCO, BCPS, CGP Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA
Mary J Macleod BSc, MBChB, PhD, FRCP University of Aberdeen, Aberdeen, UK
Jennifer Martin MA, MBBS, PhD University of Queensland, Brisbane, QLD, Australia
Glenn Matfin MB, ChB National Health Service, London, UK
Patricia Mcgettigan MD, FRCPI, FRACP Hull York Medical School, Hull/York, UK
James McLay University of Aberdeen, Aberdeen, UK
Christoph Meier PhD, MSc University Hospital Basel, Basel, Switzerland
Yola Moride PhD, FISPE University of Montreal, Montreal, QC, Canada
Vicky Parikh MD, PPH Mid-Atlantic Medical Research Centers, Hollywood, MD, USA
Emilio Perucca University of Pavia, Pavia, Italy
Philip Pierce MD Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
Munir Pirmohamed BChB, MRCO, PhD, FRCP, FBPharmacolS University of Liverpool, Liverpool, UK
Thomas M. Polasek BSc, BPharm, PhD Flinders University, Adelaide, SA, Australia
Amrit Ray MD, MBA Johnson & Johnson Pharmaceuticals Group, Titusville, NJ, USA
Michael Rieder MD, PhD Childrens Hospital of W. Ontario, London, ON, Canada
Luis Rios-Nogales MD, PhD AstraZeneca, Miami, FL, USA
Greg Roberts Bpharm Repatriation General Hospital, Daw Park, SA, Australia
Allen Root University of South Florida, USA
Jennifer Ross MSc NHS Grampian, Aberdeen, UK
Sarah Ross University of Aberdeen, Aberdeen, UK
Dietrich Rothenbacher MD, PhD University of Ulm, Ulm, Germany
Andrew Rowland Flinders University, Australia
Leo Russo MS, PhD Shire Pharmaceuticals, Wayne, PA, USA
Carmelo Scarpignato MD, DSc, FRCP, FACP, FACG University of Parma, Parma, Italy
Michael Schachter Schachter BSc, MB, FRCP Imperial College London, UK
Rashmi Shah BSc, MBBS, FRCP, FRCP, MD, FFPM, HonFBPhS Rashmi Shah Consultancy Ltd, Gerrards Cross, UK
Michael Sorich Flinders University, Australia
Johanna Strandell PhD, MSc, Pharm Uppsala Monitoring Centre, Uppsala, Sweden
Scott Twaddell BMedSc, BMed, GCClinTox, FRACP University of Newcastle, Newcastle, NSW, Australia
Allen Vaida PharmD, BSc Institute of Safe Medication Practices, Horsham, PA, USA
Tjeerd Van Staa MD, PhD, MA, MSc Medicines and Healthcare Products Regulatory Agency, London, UK
David Williams PhD, FRCP Royal College of Surgeons, Eire, Ireland
Richard Woodman PhD, MBiostats, MMedSco, BSc 2005-2010
Jane Woolley PhD Medicines and Healthcare products Regulatory Agency, USA
  • Chemical Abstracts Service (CAS)
  • Clarivate Analytics: Emerging Sources Citation Index (ESCI)
  • ProQuest
  • PubMed
  • SCOPUS
  • Web of Science (Clarivate Analytics)
  • Manuscript Submission Guidelines: Therapeutic Advances in Drug Safety

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    All articles are listed on PubMed.

    Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/tads to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

    Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Drug Safety will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. Open Access
    2. Article Processing Charge (APC)
    3. Article Types
    4. Editorial policies
      4.1 Peer review policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical trials
      4.8 Reporting guidelines
      4.9 Data
    5. Publishing policies
      5.1 Publication ethics
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Formatting
      6.2 Artwork, figures and other graphics
      6.3 Supplementary material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 ORCID
      7.2 Information required for completing your submission 
      7.3 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Online First publication
      8.3 Access to your published article 
      8.4 Promoting your article
    9. Further information

    1. Open Access

    Therapeutic Advances in Drug Safety is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

    2. Article Processing Charge (APC) 

    From 1st January 2019, this journal will become fully open access. To facilitate this transition, all articles will be published under a Creative Commons licence.

    There will be no article processing charge (APC) payable for publication in the journal for an introductory period.

    3. Article Types

    Therapeutic Advances in Drug Safety considers the following article types for publication: 

    Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature.

    Review Articles. These manuscripts are usually commissioned by the Editors, but the following types of high-quality review will be considered:
    (a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
    (b) Perspective reviews – review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic; 
    (c) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy.

    Systematic Reviews – these should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).

    Meta-analyses – these should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).

    Case Reports – these structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.

    Case Series – these descriptive structured reports (which do not involve formal hypotheses or pre-specified methodology or analyses) of a small group of patients should include a full review of the pertinent literature and a section on implications for clinical care.  

    Study Protocols – these can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.

    Letters to the Editor – these brief opinion pieces should be as concise as possible, usually no more than 1000 words.

    The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Drug Safety welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Drug Safety operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author.  Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations.  All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.

    As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

    • The reviewer should have no prior knowledge of your submission
    • The reviewer should not have recently collaborated with any of the authors
    • Reviewer nominees from the same institution as any of the authors are not permitted 

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    2. Drafted the article or revised it critically for important intellectual content,
    3. Approved the version to be published,
    4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. 

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References. 

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    4.4 Funding 

    Therapeutic Advances in Drug Safety requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    4.5 Declaration of conflicting interests 

    It is the policy of Therapeutic Advances in Drug Safety to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number. 

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    4.7 Clinical trials

    Therapeutic Advances in Drug Safety endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

    4.8 Reporting guidelines 

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    4.9 Data  

    SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles. 

    Therapeutic Advances in Drug Safety requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at tads@sagepub.co.uk

    Back to top

    5. Publishing Policies

    5.1 Publication ethics 

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism 

    Therapeutic Advances in Drug Safety and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement   

    Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway

    Back to top

    6. Preparing your manuscript for submission

    6.1 Formatting 

    The preferred format for your manuscript is Word. Word templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    6.2 Artwork, figures and other graphics 

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    6.4 Reference style 

    Therapeutic Advances in Drug Safety adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

    If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.

    EndNote: here 
    Zotero: here

    6.5 English language editing services  

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    7. Submitting your manuscript

    Therapeutic Advances in Drug Safety is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tads to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    7.1 ORCID 

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

    The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

    7.2 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).  

    7.3 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.

    Back to top

    8. On acceptance and publication 

    8.1 SAGE Production 

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change. 

    8.2 Online First publication

    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.

    8.3 Access to your published article 

    SAGE provides authors with online access to their final article.

    8.4 Promoting your article 

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Therapeutic Advances in Drug Safety editorial office as follows:

    tads@sagepub.co.uk

    For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

    Commercial Sales Team, London, UK Tel: +44 20 7336 1205 Email: reprints@sagepub.co.uk